Kestra study shows 100% shock conversion in wearable defibrillator
Kestra Medical Technologies (KMTS) reported 100% conversion success in its ASSURE Wearable Cardioverter Defibrillator study, meeting safety and effectiveness goals. The study, involving 21,612 patients, showed a 0.0065 inappropriate-shock rate and 94% of patients with no false alarms. The company plans an algorithm update to reduce inappropriate shocks by 70%.
How this was made
The 30-second read
Why it matters
The data represent the first public disclosure of the device's efficacy, likely improving investor sentiment and supporting a price rally.
Market read
First‑time release of positive clinical trial data for a U.S. listed medical‑device company, offering material insight for traders.
What to watch
Potential competition from other wearable defibrillators and the need for insurance coverage.
Background
Kestra Medical Technologies (NASDAQ:KMTS) announced primary results from its post‑approval study of the ASSURE wearable cardioverter‑defibrillator, showing 100% shock conversion and a low inappropriate‑shock rate.
Ticker impact
Kestra Medical Technologies reported FDA‑mandated post‑approval study showing 100% shock conversion and low inappropriate‑shock rate for its ASSURE wearable defibrillator.
likely upward pressure as investors price in the successful trial results.
First disclosure of full‑shock conversion and reduced inappropriate‑shock rate provides material, novel data for a micro‑cap medical‑device company.
Market effects
Strengthens the wearable cardiac device sector and may boost peer valuations.
U.S. market focus as the study enrolled patients across 35 states.
Limited; primarily relevant to U.S. investors and medical‑device niche.
Counterpoint
If reimbursement or adoption hurdles persist, the trial success may not translate into sales.
Key entities
- companyKestra Medical Technologies
Developer of the ASSURE wearable cardioverter‑defibrillator.
- productASSURE Device
Wearable cardioverter‑defibrillator evaluated in the study.



